Cinacalcet

Drug Profile

Cinacalcet

Alternative Names: 226256-56-0; AMG-073; Cinacalcet HCL; Cinacalcet hydrochloride; KRN-1493; Mimpara; NPS-1493; Regpara; Sensipar

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Amgen; Kirin Holdings Company
  • Class Naphthalenes
  • Mechanism of Action Calcium channel agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercalcaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercalcaemia; Primary hyperparathyroidism; Secondary hyperparathyroidism
  • No development reported Cardiovascular disorders

Most Recent Events

  • 31 Aug 2017 Registered for Secondary hyperparathyroidism (In children, In adolescents) in European Union, Norway, Iceland, Liechtenstein (PO)
  • 23 Jun 2017 Preregistration for Secondary hyperparathyroidism (In adolescents, In children) in European Union (PO) before June 2017
  • 23 Jun 2017 The EMA's CHMP adopts a positive opinion for cinacalcet in Secondary hyperparathyroidism (In children, Treatment-experienced)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top